Table 5.
ISWI-contaning complexes in cancer and their functions
| Complex components | Cell types or tumors | Functions |
|---|---|---|
| SNF2L-NURF complex-Circ-DONSON | GC cell lines (BGC-823, AGS, MGC-803, MKN74, HGC-27 and SGC-7901) | Activating SOX4 transcription, which leads to the proliferation, migration and invasion of GC cells |
| SNF2L-NURF complex-LncRNA DLEU1 | Human colorectal cell lines (HCT8 and SW480 cell) | Initiating KPNA3 expression and promoting cell proliferation, migration and invasion |
| SNF2L-NURF complex-LncHOXA10 | Primary liver TICs | Activating HOXA10 transcription to promote the self-renewal of liver tumor initiating cells (TICs) |
| SNF2L-NURF complex-LncGata6 | Mouse intestinal stem cells | Promoting Ehf transcription, which subsequently induces Lgr4/5 expression and activation of Wnt signaling in intestinal stem cells (ISCs) |
| SNF2L-NURF complex-WASH | Mouse long term-hematopoietic stem cells | WASH assists the NURF complex in the c-Myc promoter and enhances gene transcription, which maintains the differentiation potential of long-term hematopoietic stem cells (LT-HSCs) to mature blood lineages |
| SNF2L-NURF complex-ZIC2 | Primary liver CSCs and Hep3B cell lines | Initiating OCT4 activation to maintain the self-renewal of liver CSCs |
| SNF2H-CTCF complex | MEL and OCI-M2 cells | Being recruited to the enhancer of PU.1 gene and block gene expression |
| RSF1-cyclin E1 | Renal epithelial cells | Contributing to neoplastic transformation in the presence of TP53 mutations |
| SNF2H-RSF1-NF-κB | Ovarian cancer cells lines (SKOV3, OVCAR3, and A2780) | Activating NF-κB–dependent gene expression, contributing to the development of chemoresistance |
| SNF2H-ACF1-CHRAC15-CHRAC17-KU70/80 | U2OS/TRE/I-SceI-19 cells | Playing important roles on double-strand breaks repair |
| WSTF-RUVBL2- INTS3- RUNX2 | Breast, prostate, and bone cancer cells lines (Saos2, U2OS, MDA-MB-231 and PC3) | Mounting an integrated response to DNA damage through supporting histone displacement, DNA unwinding, and stabilization of single-stranded DNA |
| WSTF-NRG3 | Colon cancer cells line (SW48) | Activating oncogenic pathways of the surrounding normal colon cells through mediating cell–cell communication |
| TIP5-EZH2 | Prostate cancer cell line (PC3) | Participating in epigenetic silencing of AOX1, FBN1, FHL2 and HOMER2 genes |
| BPTF-c-Myc | Pre-neoplastic pancreatic acinar cells | Increasing c-MYC recruitment to target genes and regulating chromatin accessibility at promoters, thus increasing target genes’ transcription |
| BPTF-P50-NF-κB | Lung cancer cell lines (A549 and NCI-H460) | Increasing COX-2 expression by binding to COX-2 promoter region, promoting tumor cell growth |
| BPTF-WDR5 | Bladder cancer cell line (LD611) | Promoting the expression of tumorigenic genes |
| RBBP7-NKX6.1 | Cervical cancer cell line (HeLa) | Serving as a repressor to bind to vimentin promoter, thus suppressing its transcription |
| RBBP7-HNF1B | Prostate cancer cell line (DU145) | Repressing SLUG expression and EMT phenotype |
| RBBP7/4-MTA2/Mi-2/HDAC1/2 -TWIST | Human and mouse breast cancer cells (MDA-MB-435 and 4 T1) | Suppressing E-cadherin transcription, inducing EMT program |
| RBBP4–BCL11A | Breast cancer cell line (SUM149) | The recruitment of RBBP4-BCL11A complexes to BCL11A-targeted genes decreases aldehyde dehydrogenase-positive breast cancer stem cells (BCSCs) and their mammosphere formation capacity |
| RBBP4-ARMC12 | Neuroblastoma cell lines (SH-SY5Y, BE(2)-C and IMR32) | Facilitating the formation of PRC2 in neuroblastoma, resulting in transcriptional repression of tumor suppressive genes |
| RBBP4-CBP/p300 | Glioblastoma cell line (T98) | Promoting DNA repair genes expression, which influences the survival against temozolomide (TMZ)therapy |
| RBBP4-LncRNA LCPAT1 | Breast cancer cell lines (MCF-7 and MDA-MB-231) | Activating MFAP2 transcription and promoting breast cancer progression |